Medicine Technology 🌱 Environment Space Energy Physics Engineering Social Science Earth Science Science
Medicine 2024-12-12

Pfizer-BioNTech vaccine for COVID-19 among children ages 5-17

JAMA Network Open
About The Study: The results of this study suggest that the BNT162b2 XBB vaccine (Pfizer-BioNTech) provided protection against COVID-19–associated hospitalization and emergency department or urgent care visits among children 5 to 17 years of age during the 2023-2024 season with estimated vaccine effectiveness point estimates ranging from 63% to 73%. 

Corresponding Author: To contact the corresponding author, Sara Y. Tartof, PhD, MPH, email Sara.Y.Tartof@kp.org.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2024.49944)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.49944?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=121224

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

END